San Antonio, Texas USA (UroToday.com) Scott Eggener, University of Chicago, discussed focal therapy in the management of prostate cancer. WE currently lag approximately 50 years behind our counterparts in breast cancer management in regards to focal therapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Focal therapy consensus statements have focused on biopsy strategies, imaging and characterizing cancer better. Specifically, inclusion criteria have been patients PSA<15 ng/ml, life expectancy > 10 years and localized prostate cancer deemed low to intermediate risk. In versus out of field failures have been defined as well as specific follow-up recommendations. There is an agreement that intermediate risk cancers are ideal. There is lack of long term data at present and concern regarding over treatment of indolent disease with potential under treatment of more aggressive cancer.
Presented by: Scott Eggener, University of Chicago
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA